Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 7/20 | 0.36 |
| ▸ | MMP3 | P08254 | 3/20 | 0.36 |
| ▸ | MMP9 | P14780 | 2/20 | 0.36 |
| ▸ | MMP12 | P39900 | 2/20 | 0.36 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.35 |
| ▸ | PSMB10 | P40306 | 3/20 | 0.35 |
| ▸ | PSMB8 | P28062 | 3/20 | 0.35 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.35 |
| ▸ | PSMB9 | P28065 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6828517 | 0.93 | ACACB (0.39) | — | |
| SCHEMBL5980987 | 0.91 | ITGB1 (0.40) | MMP1MMP3MMP9 | |
| SCHEMBL5963738 | 0.83 | ACE (0.40) | — | |
| SCHEMBL5963487 | 0.82 | TACR2 (0.45) | MMP1 | |
| SCHEMBL3361131 | 0.81 | CTSS (0.41) | — | |
| SCHEMBL5963699 | 0.78 | ACE (0.47) | MMP1MMP3MMP9 | |
| SCHEMBL9069939 | 0.72 | TSHR (0.39) | — | |
| SCHEMBL9069938 | 0.72 | TSHR (0.39) | — | |
| SCHEMBL5963614 | 0.71 | ACE (0.42) | — | |
| SCHEMBL11674845 | 0.69 | ACACB (0.54) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1430045-B1 | PYRANE DERIVATIVES AS BOTH ACE- AND NEP-INHIBITORS | NOVARTIS AG (CH) | 2006-10-11 | — | — | EP | claimed |
| US-7071169-B2 | Pyrane derivatives as both ACE-and NEP-inhibitors | NOVARTIS AG (CH) | 2006-07-04 | — | — | US | claimed |
| US-20040266698-A1 | Pyrane derivatives as both ace-and nep-inhibitors | FINK CYNTHIA ANNE (US) | 2004-12-30 | — | — | US | claimed |
| EP-1430045-A1 | PYRANE DERIVATIVES AS BOTH ACE- AND NEP-INHIBITORS | Novartis AG (CH) | 2004-06-23 | — | — | EP | claimed |
| WO-2003027091-A1 | PYRANE DERIVATIVES AS BOTH ACE- AND NEP- INHIBITORS | NOVARTIS AG (CH) | 2003-04-03 | — | — | WO | claimed |
| EP-1430045-B1 | PYRANE DERIVATIVES AS BOTH ACE- AND NEP-INHIBITORS | NOVARTIS AG (CH) | 2006-10-11 | — | — | EP | disclosed |
| US-20060194742-A1 | Pyrane derivatives as both ACE- and NEP-inhibitors | FINK CYNTHIA A | 2006-08-31 | — | — | US | disclosed |
| US-7071169-B2 | Pyrane derivatives as both ACE-and NEP-inhibitors | NOVARTIS AG (CH) | 2006-07-04 | — | — | US | disclosed |
| US-20040266698-A1 | Pyrane derivatives as both ace-and nep-inhibitors | FINK CYNTHIA ANNE (US) | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194742-A1 | Pyrane derivatives as both ACE- and NEP-inhibitors | ECE1, ECE2, AGTR1 | ALDH1A1 714/4885MMP1 1603/4885MMP3 1285/4885 |
| US-20040266698-A1 | Pyrane derivatives as both ace-and nep-inhibitors | ECE1, AGTR1, ACE | ALDH1A1 141/4885MMP1 769/4885MMP3 1245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.